Nobel physicist Giorgio Parisi takes up complexity sciences post in China
Nobel laureate Giorgio Parisi has taken up a senior position at a university in eastern China as the country strives to
attract established scientists for top-tier research.
The winner of the 2021 Nobel Prize for physics has moved from Rome to be a discipline leader at an international research centre for complexity sciences at
Beihang University's Hangzhou campus in Zhejiang province.
According to a university social media post, Beihang Communist Party secretary Zhao Changlu said he hoped Parisi would recommend more top researchers to join the university and help make it more international.
Parisi said he would endeavour to 'promote more scientific cooperation between Beihang University and Italy, as well as with the rest of Europe', according to the post.
The Hangzhou Innovation Research Institute, where Parisi will be based, is a joint project between the Zhejiang government and Beihang University, a training ground in Beijing for China's aerospace industry.
The institute was officially opened in March 2023 and aims to become 'an international education and academic collaboration platform'.
It has 20 research centres and is recruiting staff from China and abroad to join them.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
5 hours ago
- South China Morning Post
Can Hong Kong afford to jump on the mainland Chinese tech bandwagon?
Feel strongly about these letters, or any other aspects of the news? Share your views by emailing us your Letter to the Editor at letters@ or filling in this Google form . Submissions should not exceed 400 words, and must include your full name and address, plus a phone number for verification President Xi Jinping's recent criticism of local governments for blindly pursuing hot industries like artificial intelligence and new energy vehicles should serve as a wake-up call for Hong Kong. The warning highlights the risk of 'involution' or vicious competition, especially if Hong Kong simply takes 'industrial diversification' to mean following mainland trends. In recent years, Hong Kong has promoted innovation and technology, yet a closer examination reveals a concerning sameness. Although the Northern Metropolis and Cyberport appear to focus on diverse areas – life sciences, microelectronics, Web3 – they often mirror similar innovation corridors on the mainland. Xi's question – of whether all provinces in the country have to develop the same few industries – might also be asked of Hong Kong. Given that Hong Kong is spending a lower share of its gross domestic product on R&D and that these resources are spread across multiple fields, the city is less likely to achieve breakthroughs in these areas. In the meantime, as mainland provinces strengthen their industrial chains, Hong Kong's role as a connector may diminish. The Central Urban Work Conference Xi presided over also proposed improving the efficiency of existing capacity and assessing debt risk, ideas that could apply to Hong Kong.
South China Morning Post
7 hours ago
- South China Morning Post
Innovent, BeOne are poised for profits in 2025, in milestone for Chinese biotech start-ups
Innovent likely to post a first-half net profit of US$36.4 illion, and BeOne's first-half net rofit is expected to come in at US$42 million A pair of Hong Kong-listed mainland Chinese biotechnology firms are poised to turn a profit this year as their revenue from novel drugs finally outstrips costs related to research and development and marketing, according to analysts. 'Chinese biotechs have matured significantly and are creating value for Chinese patients and government payers,' said Tony Ren, head of Asia healthcare research at Macquarie Capital, in a report on July 16. '[Some will] likely turn profitable soon and no longer rely on investors for funding.' Suzhou-based Innovent Biologics, the first Chinese company to be approved to sell a drug for weight loss and diabetes, is expected to swing to a first-half net profit of 260 million yuan (US$36.4 million) from a year-earlier loss of 392.6 million yuan, according to an estimate from Zhang Jialin, Nomura's head of China healthcare research. According to a consensus estimate from Bloomberg, the company was expected to post a net profit of 472 million yuan for 2025, its first full-year profit since going public. Innovent, founded in 2011, was one of the first batch of firms to go public in 2018 under a Hong Kong listing regime that allowed drug and medical device developers with no profit or revenue to sell shares. Innovent Biologics is expected to post a first-half net profit of 260 million yuan compared with a loss of 392.6 million yuan a year earlier. Photo: Handout In the second half, Zhang estimated that Innovent would book 1 billion yuan in sales from mazdutide, a glucagon-like peptide-1 (GLP-1) weight loss drug launched in July. That would amount to a sixth of the company's total expected revenue for this year, making it a key contributor to the improved bottom line. Novo Nordisk's semaglutide, the first GLP-1 drug launched in China last year for weight loss, generated revenue of 770 million yuan in the first quarter. A researcher using a micropipette pipette in a lab. Photo: Shutterstock BeOne, a developer of oncology drugs that was established in 2010, was expected by analysts to post a net profit of US$42 million for the first half and a full-year profit of US$109.5 million. The company will announce its first-half results on August 6. Newsletter Every Saturday SCMP Global Impact By submitting, you consent to receiving marketing emails from SCMP. If you don't want these, tick here {{message}} Thanks for signing up for our newsletter! Please check your email to confirm your subscription. Follow us on Facebook to get our latest news. The company's profit growth was driven primarily by sales of its blood cancer drug zanubrutinib in the US and Europe, Zhang said. Innovent and BeOne, along with other Chinese biotech firms like Akeso, have booked billions of yuan in upfront revenue over the past few years from licensing drug candidates to multinational partners for overseas development. But despite an increase in deals in recent years, milestone payments in the drug development process were hard to predict because collaborations were often cut short due to shifting competitive considerations and regulatory hurdles, Macquarie's Ren said. For example, the US Food and Drug Administration (FDA) in March 2022 rejected an application from Eli Lilly to sell Innovent's lead oncology drug, sintilimab, to treat the most common type of lung cancer in the US, even though it was approved in China a year earlier. While the FDA recommended that an additional multi-regional clinical study be conducted, the drug has still not been approved in the US. In mid-2019, Celgene returned to BeOne the exclusive right to develop and commercialise the Chinese firm's immunotherapy drug candidate, tislelizumab, ahead of Celgene's impending acquisition by Bristol-Myers Squibb. The American drug firm already had an approved treatment in the same category. Celgene terminated the deal by paying BeOne US$150 million. In 2021, BeOne re-licensed the rights for the same drug to Switzerland's Novartis, which in 2023 returned them, citing a changing market landscape. BeOne subsequently took over the drug's development and won approvals to launch it in the European Union and the US. 'Most licensing deals, including ones from China, are small [in actual payments] and hardly affect the licensers' financial performance over the medium to long term,' Ren said.
South China Morning Post
7 hours ago
- South China Morning Post
Innovent, BeOne are poised for profits in 2025, in milestone for Chinese biotech start-ups
A pair of Hong Kong-listed mainland Chinese biotechnology firms are poised to turn a profit this year as their revenue from novel drugs finally outstrips costs related to research and development and marketing, according to analysts. Advertisement 'Chinese biotechs have matured significantly and are creating value for Chinese patients and government payers,' said Tony Ren, head of Asia healthcare research at Macquarie Capital, in a report on July 16. '[Some will] likely turn profitable soon and no longer rely on investors for funding.' Suzhou-based Innovent Biologics , the first Chinese company to be approved to sell a drug for weight loss and diabetes, is expected to swing to a first-half net profit of 260 million yuan (US$36.4 million) from a year-earlier loss of 392.6 million yuan, according to an estimate from Zhang Jialin, Nomura's head of China healthcare research. According to a consensus estimate from Bloomberg, the company was expected to post a net profit of 472 million yuan for 2025, its first full-year profit since going public. Innovent, founded in 2011, was one of the first batch of firms to go public in 2018 under a Hong Kong listing regime that allowed drug and medical device developers with no profit or revenue to sell shares. Innovent Biologics is expected to post a first-half net profit of 260 million yuan compared with a loss of 392.6 million yuan a year earlier. Photo: Handout In the second half, Zhang estimated that Innovent would book 1 billion yuan in sales from mazdutide, a glucagon-like peptide-1 (GLP-1) weight loss drug launched in July. Advertisement That would amount to a sixth of the company's total expected revenue for this year, making it a key contributor to the improved bottom line. Novo Nordisk's semaglutide, the first GLP-1 drug launched in China last year for weight loss, generated revenue of 770 million yuan in the first quarter.
